Tvardi Therapeutics (TVRD) Income towards Parent Company (2013 - 2026)

Tvardi Therapeutics has reported Income towards Parent Company for 14 years, with the latest figure at -$7.6 million in Q1 2026.

• Quarterly Income towards Parent Company rose 21.16% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.2 million (down 120.46% YoY) and the FY2025 annual result came in at -$27.8 million, up 60.73% from the prior year.
• Income towards Parent Company advanced to -$7.6 million in Q1 2026 per TVRD's latest filing, from -$8.7 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$7.1 million in Q2 2024 and troughed at -$40.0 million in Q3 2025.
• A 5-year average of -$21.9 million and a median of -$26.3 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company slumped 2499.31% in 2022, then soared 78.39% in 2024.
• Over 5 years, Income towards Parent Company stood at -$31.8 million in 2022, then decreased by 4.12% to -$33.1 million in 2023, then soared by 67.63% to -$10.7 million in 2024, then increased by 18.91% to -$8.7 million in 2025, then climbed by 13.12% to -$7.6 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$7.6 million, -$8.7 million, and -$40.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.